

Human EDIL3 Antibody

Monoclonal Mouse IgG_{2A} Clone # 670421 Catalog Number: MAB6046


DESCRIPTION		
Species Reactivity	Human	
Specificity	Detects human EDIL3 in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant human MGF-E8 is observed.	
Source	Monoclonal Mouse IgG _{2A} Clone # 670421	
Purification	Protein A or G purified from hybridoma culture supernatant	
Immunogen	Chinese hamster ovary cell line CHO-derived recombinant human EDIL3 Val17-Glu480 Accession # O43854	
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 µm filtered solution in PBS.	

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.


	Recommended Concentration	Sample
Western Blot	2 μg/mL	See Below

DATA



Detection of Human EDIL3 by Western Blot. Western blot shows lysates of human lung tissue. PVDF membrane was probed with 2 μ g/mL of Mouse Anti-Human EDIL3 Monoclonal Antibody (Catalog # MAB6046) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for EDIL3 at approximately 54 kDa (as indicated). This experiment was conducted under non-reducing conditions and using Immunoblot Buffer Group 1.

PREPARATION AND STORAGE		
Reconstitution	Sterile PBS to a final concentration of 0.5 mg/mL.	
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C	
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution.	







Human EDIL3 Antibody

Monoclonal Mouse IgG_{2A} Clone # 670421 Catalog Number: MAB6046

BACKGROUND

EGF-like repeat and discoidin I-like domain-containing protein 3 (EDIL3; also Del-1 and integrin-binding DEL1) is a 52 kDa extracellular matrix protein that is expressed by endothelial tissues during embryonic vascular development (1). Human EDIL3 is synthesized as a precursor with a 16 amino acid (aa) signal sequence and a 464 aa mature chain. The mature chain is composed of three epidermal growth factor (EGF) repeats and two discoidin-I-like domains (1). The second EGF repeat contains an RGD motif (1). Splicing variants produce two isoforms for human EDIL3. Isoform 2 has an A->G substitution at aa 66 and a deletion of aa 67-76 found in isoform 1. Mature human EDIL3 shares 96% aa sequence identity with mature mouse EDIL3. The RGD motif of EDIL3 binds αν β5 integrin, which, in turn, leads to increased angiogenic transcription factor HoxD3 expression (2). HoxD3activates αν β3 and uPA, resulting in the transformation of resting endothelial cells to an angiogenic state (2-4). EDIL3 becomes quiescent at the time of birth, and is no longer expressed in normal adult tissues. It has been found, however, re-expressed in a number of human tumors as well as in ischemic muscles and ischemic brain tissue, which may play an important role in adult angiogenesis (2, 5-6). EDIL3 promotes adherence and migration of endothelial cells, and acts as an endothelial cell survival agent through upregulation of BcI-2 expression (7). Exogenous application of EDIL3 has been demonstrated to augment angiogenesis and improve blood flow and tissue function in murine models of hind-limb ischemia (6, 8), cardiac ischemia (9) and cerebral ischemia (2). EDIL3 has also been shown to be an endogenous inhibitor of inflammatory cell recruitment by interfering with the integrin LFA-1-dependent leukocyte-endothelial adhesion (10).

References:

- 1. Hidai, C. et al. (1998) Genes Dev. 12:21.
- 2. Fan, Y. et al. (2008) Brain Res. 1219:1.
- 3. Penta, K. et al. (1999) J. Biol. Chem. 274:11101.
- 4. Rezaee, M. et al. (2002) Am. J. Physiol. Heart Circ. Physiol. 282:H1924.
- 5. Aoka, Y. et al. (2002) Microvasc. Res. 64:148.
- 6. Ho, H.K. et al. (2004) Circulation 109:1314.
- 7. Pollman, M.J. et al. (1999) J. Cell Physiol. 178:359.
- 8. Zhong, J. et al. (2003) J. Clin. Invest. 112:30.
- 9. Kown, M.H. et al. (2003) Ann. Thorac. Surg. 76:1246.
- 10. Choi, E.Y. et al. (2008) Science 322:1101

